Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Safety Study of MGD006 in Relapsed / Refractory Acute Myeloid Leukemia (AML) or Intermediate-2 / High Risk MDS
Multiple Cancer Types
The primary goal of this Phase 1 / 2, dose-escalation study, is to determine the maximum tolerated dose level of flotetuzumab (MGD006) in patients with AML whose disease is not expected to benefit from cytotoxic chemotherapy. Studies will also be done to see how the drug acts in the body (pharmacokinetics [PK], pharmacodynamics) and to evaluate potential anti-tumor activity of flotetuzumab.
Leukemia,
Myelodysplastic Syndrome,
Phase I
I/II
Byrne, Michael
NCT02152956
VICCHEMP1828
